Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02289144
Title Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Texas Southwestern Medical Center
Indications

thyroid gland cancer

Therapies

Ceritinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST